4584.T
Kidswell Bio Corporation
グロース · 医薬品 · 医薬品 · JP
JPY 161.00
−3.59%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.1B | 6.6B | 5.1B | 2.4B | 2.8B |
| Cost of Revenue | 1.1B | 4.8B | 3.4B | 1.4B | 1.3B |
| Gross Profit | 597.2M | 1.7B | 1.6B | 1.0B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 412.6M | 1.9B | 1.6B | 2.4B | 2.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 412.6M | 1.9B | 1.6B | 2.4B | 2.1B |
| Cost and Expenses | 6.8B | 6.7B | 5.1B | 3.8B | 3.3B |
| Operating Income (EBIT) | 248.0M | (138.0M) | 27.0M | (1.3B) | (550.0M) |
| Non-Operating | |||||
| Interest Income | — | 5.1M | 767.0K | 8.0K | 12.0K |
| Interest Expense | 8.9M | 47.6M | 39.4M | 35.7M | 32.8M |
| Net Interest Income | — | (42.6M) | (38.6M) | (35.6M) | (32.7M) |
| Other Non-Op Income/Expense | (9.0M) | (236.4M) | (22.7M) | (54.0M) | (73.8M) |
| Non-Operating Income (excl Interest) | 403.0K | 41.2M | 26.1M | 6.8M | 4.0M |
| EBT (Pre-Tax Income) | 175.6M | (402.9M) | 72.9M | (1.4B) | (656.2M) |
| Income Tax Expense | 18.5M | 11.1M | 94.0M | 1.6M | 1.2M |
| Bottom Line | |||||
| Net Income | 24.0M | (413.0M) | (21.0M) | (1.4B) | (657.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 24.0M | (413.0M) | (21.0M) | (1.4B) | (657.0M) |
| Per Share | |||||
| Basic EPS | ¥1 | (¥8) | (¥1) | (¥40) | (¥21) |
| Diluted EPS | ¥1 | (¥8) | — | — | — |
| Revenue Per Share | ¥146 | ¥135 | ¥125 | ¥69 | ¥88 |
| Shares | |||||
| Basic Shares Outstanding | 48.5M | 48.8M | 40.5M | 35.3M | 31.7M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (137.8M) | 27.9M | (1.3B) | (549.1M) |
| D&A | — | 249.0K | 900.0K | 921.0K | 932.0K |
| EBIT | 248.0M | (138.0M) | 27.0M | (1.3B) | (550.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026